Marker Therapeutics (MRKR) said Thursday it has agreed to sell securities worth $16.1 million to investors including Blue Owl Healthcare Opportunities (OWL), New Enterprise Associates and Aisling Capital in a private placement.
Marker said it will sell about 5 million shares, or pre-funded warrants, and warrants to buy up to around 5 million shares at a price of $3.20 per share and accompanying warrant.
Net proceeds will be allocated toward supporting the phase 1 Apollo trial studying the company's multi-antigen recognizing T cell product, it added.
The company's shares were down 4.2% in recent trading.
Price: 3.81, Change: -0.22, Percent Change: -5.46
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。